Sign in
Not yet taking people in ItalyPhase 2

Denosumab compared with zoledronic acid for erosive hand osteoarthritis in people with osteoporosis

Compares denosumab and zoledronic acid in people with erosive hand osteoarthritis and osteoporosis.

Key facts

Who runs it
Azienda Ospedaliera Universitaria Integrata Verona
Where
Padova and Verona, ItalySee the 2 sites
Registry title
Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)
Status
Not yet recruiting
Phase
Phase 2
People taking part
150 people, planned
Started
30 Sept 2026
Expected to end
30 Sept 2028
Type of study
Interventional
Record updated
14 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men aged 50 or older and post-menopausal women with osteoporosis and erosive hand osteoarthritis. They must never have had osteoporosis medicine and must be able to start denosumab or zoledronic acid.

Age
Men ≥50 years; post-menopausal women (record minimum age 18 Years)
Sex
Men and post-menopausal women
Disease stage
Erosive (inflammatory) hand osteoarthritis with past inflammatory flares and current signs of inflammation in the finger joints. At least 1 finger joint must look like a 'J' or 'E' phase joint on X-ray. Osteoporosis must also be present.
Earlier treatment
No earlier anti-osteoporosis medicine. No IV bisphosphonates ever, no oral bisphosphonates within 12 months before screening, no denosumab ever, and no other drugs like romosozumab, PTH analogs or SERMs.
Biomarker or test result
Bone density (BMD) T-score of ≤ -2.5 at the lumbar spine, total hip or femoral neck, or a T-score of ≤-2.0 there plus an existing major osteoporotic (MOF) fracture.

Main reasons for not taking part

  • Cancer within the last 5 years, except some skin cancers or cervical carcinoma in situ
  • Other inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis or gout
  • Past or active jaw bone death (ONJ), active dental infection or unhealed mouth surgery
  • Kidney filtration (eGFR) < 35 mL/minute/1.73 m^2, low blood calcium or vitamin D < 20 ng/mL (<49.9 nmol/L)
  • Past solid organ or bone marrow transplant, or other bone diseases

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Men ≥50 years of age and post-menopausal women with osteoporosis naïve to any anti-osteoporosis medication candidate to treatment to either denosumab of zoledronic acid
  • Subjects with hand OA having suffered from transient inflammatory attacks of the interphalangeal finger joints characteristic for what has been termed ‘inflammatory’ or ‘erosive’ hand OA
  • Subjects with hand OA showing inflammatory signs, either clinically or ultrasonographically, of the interphalangeal finger joints
  • Subjects with hand OA in which at least 1 interphalangeal finger joint has the typical appearance on the X-rays of a ‘J’ or ‘E’ phase joint as defined by the criteria mentioned above
  • Able and willing to give written informed consent and to comply with the requirements of the study protocol
  • A baseline BMD T-score of ≤ -2.5 at the lumbar spine, total hip, or femoral neck or baseline T-score of ≤-2.0 at the lumbar spine, total hip, or femoral neck + a prevalent MOF fracture
  • Signed informed consent for participation in the study and for the processing of personal data

Who cannot take part

  • No past IV bisphosphonates at any time, or any oral bisphosphonate use within 12 months before screening
  • No past treatment with denosumab
  • Recipient of an investigational drug within 4 weeks prior to study drug administration or within 5 half-lives of the investigational drug, whichever is longer
  • No past treatment with other anti-osteoporosis medications (romosozumab, PTH analogs, SERMs etc.)
  • Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma or localized squamous cell carcinoma of the skin)
  • Contraindication to, or poorly tolerant of denoosumab therapy (including hypersensitivity to the drug and any excipients)
  • Contraindication to, or poorly tolerant of zoledronic acid therapy (including hypersensitivity to the drug and any excipients)
  • History of atypical femur fracture
  • Unstable systemic medical condition
  • History of Addison disease
  • History of osteomalacia
  • History of osteonecrosis of the jaw (ONJ)
  • History or presence of inflammatory or erosive arthritides other than erosive hand osteoarthritis (EHOA), including rheumatoid arthritis, psoriatic arthritis, crystal-induced arthritis, connective tissue disease-related arthritis, and spondyloarthritis
  • Active osteonecrosis of the jaw (ONJ), unhealed oral surgery, active dental infection, or planned urgent invasive dental procedure that is considered incompatible with safe initiation of study treatment
  • History of anorexia nervosa, bulimia (by history or physical) or obvious malnutrition
  • History of Paget’s disease of bone
  • Other bone diseases which affect bone metabolism
  • History of any solid organ or bone marrow transplant
  • Intolerance to calcium supplements, vitamin D supplements
  • Hypercalcemia >10% above upper limit of normal (ULN)
  • Elevated transaminases or total bilirubin ≥ 2.0 x ULN
  • Hypocalcemia below lower limit of normal (LLN)
  • Estimated glomerular filtration rate < 35 mL/minute/1.73 m^2 at the time of screening/randomization
  • Not a good candidate for study participation in opinion of investigator
  • Uncontrolled hyperthyroidism
  • Uncontrolled hypothyroidism
  • Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (<49.9 nmol/L)

Where in Italy

  • Azienda Ospedaliera di PadovaPadova, ItalyNot yet recruiting
  • Azienda Ospedaliera Universitaria Integrata VeronaVerona, ItalyNot yet recruiting

About the trial

What the trial wants to find out

To demonstrate the reduction in the progression of erosion volume in the denosumab group vs zoledronic acid group

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)
Plain-language title
Denosumab compared with zoledronic acid for erosive hand osteoarthritis in people with osteoporosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
14 August 2026